{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:20:21Z","timestamp":1783617621044,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant therapy (NAT) has been increasingly promoted for treating early-stage breast cancer (BC), which significantly improves the adoption of breast-conserving surgery (BCS). However, concerns related to the oncological safety of BCS versus mastectomy remain unelucidated. The present study compared survival outcomes between patients treated with BCS and those treated with mastectomy after NAT through stratified analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included female BC patients who underwent radical surgery after NAT at the Peking University First Hospital and Cancer Hospital of Chinese Academy of Medical Sciences from January 2013 to December 2021. Propensity score matching (PSM) was used to minimize the selection bias. Overall survival (OS) and disease-free survival (DFS) were compared between patients receiving BCS and mastectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 994 patients were enrolled, including 285 patients treated with BCS and 709 patients treated with mastectomy. Following PSM, patients were assigned to the BCS (n = 258) and mastectomy (n = 258) groups; these two groups were well balanced regarding clinical and pathological characteristics. The 5-year OS rate (90.5%\n                      <jats:italic>vs<\/jats:italic>\n                      . 95.8%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.535) and DFS rate (86.3%\n                      <jats:italic>vs<\/jats:italic>\n                      . 86.9%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.648) of the mastectomy group were identical to those of the BCS group in the matched cohort. Stratified analysis revealed that mastectomy was an independent adverse prognostic factor for OS (hazard ratio [HR]: 2.158, 95% CI: 1.254\u20134.954,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.034) and DFS (HR: 2.914, 95% CI: 1.713\u20135.422,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.010) in patients with positive lymph nodes. Additionally, age-based stratification showed that mastectomy was an independent prognostic factor for DFS in BC patients aged &amp;gt; 40 years (HR: 2.471, 95% CI: 1.082\u20135.643,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.022).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BCS does not affect OS and DFS in BC patients treated with NAT. However, it should be noted that BCS provides a substantial survival benefit as compared to mastectomy in patients with clinically positive lymph nodes and those aged &amp;gt; 40 years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1681937","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:30:07Z","timestamp":1767591007000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of overall survival and disease-free survival for breast-conserving surgery and mastectomy in breast cancer patients receiving neoadjuvant therapy: a matched case-control study from two institutions"],"prefix":"10.3389","volume":"15","author":[{"given":"Xueqian","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer","volume":"347","author":"Fisher","year":"2002","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70042-6","article-title":"Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial","volume":"13","author":"Liti\u00e8re","year":"2012","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2013.3049","article-title":"Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer","volume":"149","author":"Agarwal","year":"2014","journal-title":"JAMA Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08829-4","article-title":"Breast-conserving therapy is associated with improved survival compared with mastectomy for early-stage breast cancer: A propensity score matched comparison using the national cancer database","volume":"28","author":"Wrubel","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30067-5","article-title":"10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study","volume":"17","author":"van Maaren","year":"2016","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31034","article-title":"Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients","volume":"142","author":"Lagendijk","year":"2018","journal-title":"Int J Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10549-022-06725-x","article-title":"Survival outcomes for breast conserving surgery versus mastectomy among elderly women with breast cancer","volume":"196","author":"Xie","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-09591-x","article-title":"Survival of breast-conserving surgery plus radiotherapy versus total mastectomy in early breast cancer","volume":"28","author":"Kim","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1603691","article-title":"I-SPY 2\u2013toward more rapid progress in breast cancer treatment","volume":"375","author":"Carey","year":"2016","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2018.07.008","article-title":"Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back","volume":"41","author":"Rubio","year":"2018","journal-title":"Breast"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12993-0","article-title":"Survival after breast-conserving surgery compared with that after mastectomy in breast cancer patients receiving neoadjuvant chemotherapy","volume":"30","author":"Gwark","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05966-y","article-title":"Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study","volume":"185","author":"Simons","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05821-0","article-title":"Comparisons of breast conserving therapy versus mastectomy in young and old women with early-stage breast cancer: long-term results using propensity score adjustment method","volume":"183","author":"Wang","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B14","article-title":"Prognostic and predictive factors in breast cancer by immunohistochemical analysis","volume":"11","author":"Allred","year":"1998","journal-title":"Mod Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.clbc.2020.01.011","article-title":"Improved prognostication for the updated AJCC breast cancer pathological prognostic staging varied in higher-stage groups","volume":"20","author":"Hu","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.21037\/tbcr-22-21","article-title":"Chinese society of clinical oncology (CSCO) breast cancer guidelines 2022","volume":"3","author":"Jiang","year":"2022","journal-title":"Transl Breast Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605939","article-title":"Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer","volume":"103","author":"Guiu","year":"2010","journal-title":"Br J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002313","article-title":"A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy","volume":"267","author":"Kuerer","year":"2018","journal-title":"Ann Surg"},{"key":"B20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10549-022-06725-x","article-title":"Survival outcomes for breast conserving surgery versus mastectomy among elderly women with breast cancer","volume":"196","author":"Xie","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znab145","article-title":"Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: meta-analysis","volume":"108","author":"Fancellu","year":"2021","journal-title":"Br J Surg"},{"key":"B22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1186\/s12885-021-08429-9","article-title":"Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy","volume":"21","author":"Guo","year":"2021","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13784-x","article-title":"Breast-conserving therapy is associated with improved survival without an increased risk of locoregional recurrence compared with mastectomy in both clinically node-positive and node-negative breast cancer patients","volume":"30","author":"Vasilyeva","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12190-z","article-title":"Impact of locoregional treatment on survival in young patients with early-stage breast cancer undergoing upfront surgery","volume":"29","author":"Orozco","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-2909-6","article-title":"Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients","volume":"20","author":"Shin","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12282-020-01158-0","article-title":"Prognostic factors for breast cancer patients with T1\u20132 tumors and 1\u20133 positive lymph nodes and the role of postmastectomy radiotherapy in these patients","volume":"28","author":"Zhao","year":"2021","journal-title":"Breast Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1681937\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:30:08Z","timestamp":1767591008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1681937\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":27,"alternative-id":["10.3389\/fonc.2025.1681937"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1681937","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1681937"}}